ID   293T/ACE2 [Japan 2021]
AC   CVCL_B0XR
DR   Wikidata; Q108819503
RX   PubMed=33686154;
CC   Group: SARS-CoV-2 research cell line.
CC   Virology: Highly susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33686154).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:13557; ACE2.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Klebsiella pneumoniae transposon Tn5 neo.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P03070; Simian virus 40 (SV40) large T antigen.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P13249; Streptomyces alboniger pac (PuroR).
CC   Transformant: NCBI_TaxID; 28285; Human adenovirus C serotype 5.
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40) (Note=tsA).
CC   Derived from site: In situ; Fetal kidney; UBERON=UBERON_0002113.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0063 ! HEK293T
SX   Female
AG   Fetus
CA   Transformed cell line
DT   Created: 23-09-21; Last updated: 14-08-25; Version: 10
//
RX   PubMed=33686154; DOI=10.1038/s41598-021-84882-7; PMCID=PMC7940632;
RA   Uemura, Kentaro
RA   Sasaki, Michihito
RA   Sanaki, Takao
RA   Toba, Shinsuke
RA   Takahashi, Yoshimasa
RA   Orba, Yasuko
RA   Hall, William W.
RA   Maenaka, Katsumi
RA   Sawa, Hirofumi
RA   Sato, Akihiko
RT   "MRC5 cells engineered to express ACE2 serve as a model system for the
RT   discovery of antivirals targeting SARS-CoV-2.";
RL   Sci. Rep. 11:5376.1-5376.9(2021).
//